Pay in 4 interest-free payments of $7.07 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Employers only pay when predefined outcomes are achieved Guaranteed improvements in A1C, weight loss, and deprescription of GLP-1s and other medications ROI is validated using pharmacy and medical claims data Reported outcomes include a 2.2-point average A1C reduction for members with starting A1C greater than8.0 and a 14-pound average weight loss for members with a BMI greater than 30, based on internal data from Twin Healths commercial populations as of September 2024 Demonstrated reductions in diabetes-related pharmacy spend while maintaining clinical appropriateness Precision medication management Employers can start by using claims and clinical data to identify risk levels and guide GLP-1 eligibility
I was exhaus
First-time users were defined as individuals who did not have GLP-1 RAs listed on their health records for at least 365 days and who only initiated the medications as a second-line treatment to metformin
The bound Fab was eluted with 25 mM sodium citrate, pH 3.2 and pooled for further purification by size-exclusion chromatography on a Superdex75 column (GE Healthcare) in phosphate buffered saline (PBS)
Cancers (Basel) , 14 (14), 3461
US$ 20.06
US$ 27.15
US$ 29.30
US$ 24.07
US$ 22.95
US$ 26.81
US$ 22.90
US$ 24.34
US$ 24.84
US$ 21.62
